Lercanidipino Aurovitas Spain

Lercanidipine Hydrochloride, the active ingredient in Lercanidipino Aurovitas Spain, is a calcium channel blocker presented as an oral tablet for oral use. It is indicated for the treatment of hypertension in adult patients. GNH USA supplies Lercanidipino Aurovitas Spain as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Lercanidipine Hydrochloride is a calcium channel blocker used to manage elevated blood pressure within the cardiovascular disease pathway.

Hypertension: lowers systolic and diastolic blood pressure, helping to reduce the risk of cardiovascular events.

Lercanidipine Hydrochloride may cause a range of adverse reactions.

Common Side Effects: - Headache: mild to moderate intensity. - Flushing: transient warmth and redness of the skin. - Peripheral edema: swelling of the ankles or lower legs. - Dizziness: especially upon standing. - Tachycardia: increased heart rate. - Nausea: occasional upset stomach.

Serious or Rare Side Effects: - Severe hypotension: marked drop in blood pressure requiring medical attention. - Angioedema: swelling of face, lips, tongue, or throat. - Hepatic dysfunction: elevated liver enzymes or hepatitis. - Allergic reactions: rash, pruritus, or anaphylaxis. - Myocardial infarction: rare occurrence of heart attack. - Cardiac arrhythmia: irregular heart rhythm.

Before initiating therapy, clinicians should consider several safety measures.

Monitor blood pressure: ensure adequate control without excessive lowering. Assess liver function: evaluate hepatic enzymes periodically. Caution in elderly patients: start with lower doses due to altered pharmacokinetics. Avoid abrupt discontinuation: taper to prevent rebound hypertension. Review concomitant antihypertensives: adjust doses to avoid additive hypotension. Store at room temperature: keep in the original pack, protect from moisture.

Lercanidipine Hydrochloride can interact with various medicines, influencing its efficacy and safety.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may increase plasma levels. - Concurrent use with other calcium channel blockers: risk of excessive vasodilation. - Combination with potent antihypertensives (e.g., ACE inhibitors, ARBs) leading to severe hypotension.

Moderate Interactions (Monitor Closely): - Grapefruit juice: can modestly raise drug concentrations. - CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce effectiveness. - Non‑steroidal anti‑inflammatory drugs (NSAIDs): potential impact on renal function and blood pressure control.